New Patent for CellTrend

CellTrend was the first to describe autoantibodies against GLP-1R and has filed a patent application. This patent covers a test system for the diagnosis, prognosis, and treatment monitoring of myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS) in patients. The anti-GLP-1R antibody can only be determined by CellTrend using serum analysis.  

Details

ME/CFS Conference 2025 in Berlin

The 3rd International ME/CFS Conference on May 12 and 13, 2025 in Berlin was a complete success. Organized by the Charité Fatigue Center (headed by Prof. Dr. Carmen Scheibenbogen), experts from all over the world gave lectures on aspects of pathogenesis, diagnostics and – most importantly – treatment options. The importance of the GPCR autoantibody…

Details

Price adjustment

Dear customers, Thank you for your trust in our products and services. Due to the increased costs of our consumables in recent years, we have had to adjust our prices, which have been in force since 2018. We ask for your understanding that this increase is necessary in order to be able to guarantee you…

Details

International ME/CFS Conference 2025

Under the direction of Prof. Dr. Carmen Scheibenbogen (Charité, Berlin), the 3rd International Meeting of the Charité Fatigue Center will take place on 12.05.25 and 13.05.25. The two-day hybrid conference will be broadcast live from the Harnack House of the Max Planck Society in Berlin and will present the latest research findings by physicians and…

Details